Biostar Pharmaceuticals (BSPM.OB) received a China patent for Aoxing Ganbao, an external use TCM treatment for hepatitis B (see story). Biostar already has name recognition in the hepatitis B sector with its flagship product, Xin Aoxing Oleanolic Acid Capsules. Xin Aoxing Oleanolic capsules, which is the only OTC oral hepatitis treatment product approved by the SFDA, generates about 50% of Biostar’s revenues.
News 
Market Data 
Discover 
